| Zacks Company Profile for Prenetics Global Limited (PRE : NSDQ) |
|
|
| |
| • Company Description |
| Prenetics, a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Their prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, their joint venture with renowned scientist Prof. Dennis Lo, underscores their unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, their treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances their global impact on health, truly embodying their commitment to 'enhancing life through science'.
Number of Employees: 285 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $7.82 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 78,376 shares |
| Shares Outstanding: 12.20 (millions) |
| Market Capitalization: $95.44 (millions) |
| Beta: 0.15 |
| 52 Week High: $11.99 |
| 52 Week Low: $3.09 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-2.49% |
-6.15% |
| 12 Week |
95.01% |
64.03% |
| Year To Date |
34.83% |
26.27% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
Unit 703-706 K11 Atelier King's Road 728 King's Road
-
Quarry Bay,K3 00000
HKG |
ph: -
fax: - |
None |
http://www.prenetics.com |
|
|
| |
| • General Corporate Information |
Officers
Yeung Danny Sheng Wu - Chairperson and Chief Executive Officer
Lo Hoi Chun - Chief Financial Officer
Cheng Yin Pan - Independent Director
Kathryn Henry - Independent Director
Chiu Wing Kwan Winnie - Independent Director
|
|
Peer Information
Prenetics Global Limited (CORR.)
Prenetics Global Limited (RSPI)
Prenetics Global Limited (CGXP)
Prenetics Global Limited (BGEN)
Prenetics Global Limited (GTBP)
Prenetics Global Limited (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G72245122
SIC: 3826
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 10/06/25
|
|
Share - Related Items
Shares Outstanding: 12.20
Most Recent Split Date: 11.00 (0.07:1)
Beta: 0.15
Market Capitalization: $95.44 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.71 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 10/06/25 |
|
|
|
| |
